COVID-19 Vaccine and Infusion Code Fee Schedule

The Centers for Medicare and Medicaid Services (CMS) have announced new Healthcare Common Procedure Coding System (HCPCS) codes for healthcare providers to use when treating patients for the novel coronavirus (COVID-19). Additionally, The American Medical Association (AMA) has announced new vaccine-specific Current Procedural Terminology (CPT®) codes to report immunizations for the novel coronavirus (SARS-CoV-2). In response, the Medicaid fee-for-service (FFS) program is reimbursing for these codes at 100% of the Medicare reimbursement rate. The following fee schedule is a summary of the codes, their descriptions, their effective dates, and the FFS reimbursement rate.

If you have any questions about the contents of this fee schedule, please contact Christa Smith at christa.smith@maryland.gov.

For questions related to MCOs and Self-Referred Services, please contact Pam Williams at pam.williams@maryland.gov.

Revision Date: 9/15/2021

COVID-19 Vaccine and Infusion Codes Fee Schedule

Vaccination products will be made available to providers at no cost by the federal government for the foreseeable future; therefore, only the cost of administration will be reimbursed. FFS Medicaid intends to reimburse for vaccine administration in alignment with the Medicare rate.

Vaccine Products				
CPT Code	**Labeler Name**	**Description**	**Effective Date**	**FFS Rate**
91300	Pfizer	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	12/11/20	$0.00
91301	Moderna	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	12/18/20	$0.00
91303	Janssen	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19] vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, $5x10^{10}$ viral particles/0.5ml dosage, for intramuscular use	2/27/2021	$0.00

Vaccine Administration					
CPT Code	**Labeler Name**	**Description**	**Effective Date**	**FFS Rate (Claims with DOS through 3/21/2021)**	**FFS Rate (Claims with DOS on or after 3/22/2021)**
0001A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	12/11/20	$16.94	$40.00
0002A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	12/11/20	$28.39	$40.00
0003A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose	8/12/2021	N/A	$40.00
0004A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; Booster	9/3/2021	Code not active during this time	$40.00

0011A	Moderna	Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	12/18/20	$16.94	$40.00
0012A	Moderna	Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose	12/18/20	$28.39	$40.00
0013A	Moderna	Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; third dose	8/12/2021	Code not active during this time	$40.00
0031A	Janssen	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservation free, $5x10^{10}$ viral particles/0.5 mL dosage, single dose	2/27/2021	$28.39	$40.00

COVID-19 Infusion Therapy

On November 9, 2020, the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for the investigational monoclonal antibody therapy, bamlanivimab, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Bamlanivimab will be made available to providers at no cost by the federal government for the foreseeable future; therefore, only the cost of administration will be reimbursed. The Department intends to set the FFS reimbursement rate at the same rate as Medicare.

Bamlanivimab may only be administered in settings in which health care providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary. Additional information

regarding limitations for authorized use can be found in the Centers for Medicare and Medicaid Services (CMS) guidance and the fact sheet issued by the manufacturer.

November 21, 2021, Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19. Casirivimab and imdevimab must be administered together by intravenous (IV) infusion.

Casirivimab and Imdevimab fact Sheet for Health Care Providers

On May 26, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death. This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions.

Sotrovimab Health Care Providers Fact Sheet

On June 24, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the drug Actemra (tocilizumab) for the treatment of hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Actemra is not authorized for use in outpatients with COVID-19.

Tocilizumab Health Care Providers Fact Sheet

Monoclonal Antibodies and Administration				
HCPCS Code	**Labeler Name**	**Description**	**Effective Date**	**FFS Rate**
Q0239	Eli Lilly	Injection, bamlanivimab, 700 mg	11/10/20	$0.00
M0239	Eli Lilly	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	11/10/20	$309.60
Q0243	Regeneron	Injection, casirivimab and imdevimab, 2400 mg	11/21/20	$0.00

M0243	Regeneron	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring	11/21/20	$309.60
M0245	Eli Lilly	intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	2/9/2021	$309.60
Q0245	Eli Lilly	Injection, bamlanivimab and etesevimab, 2100 mg	2/9/2021	$0.00
Q0247	GSK	Injection, sotrovimab, 500 mg	5/26/2021	$2394.00
M0247	GSK	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	5/26/2021	$450.00
Q0249	Genentech	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	6/24/2021	$6.57
M0249	Genetech	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose	6/24/2021	$450.00

M0250	Genetech	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose	6/24/2021	$450.00